Navigation Links
Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood

X15-070 is also in Phase 2 clinical trials in patients with Hodgkin's Lymphoma and in myelofibrosis with myeloid metaplasia. In multiple Phase 1 studies, GX15-070 was well-tolerated and resulted in clinical and biological activity.

The study, which is currently available in the online edition Blood, is titled, "Pre-clinical studies of the pan-Bcl inhibitor obatoclax (GX15-070) in multiple myeloma," was led by Dr. Suzanne Trudel, et al., of the Mayo Clinic of Medicine, Scottsdale, AZ, and Princess Margaret Hospital, Toronto, ON. The report will also appear in the print edition of Blood.

About Multiple Myeloma (MM)

Multiple myeloma is a type of cancer caused by malignant plasma cells that are spread throughout the bone marrow, resulting in bone erosion and interference with bone marrow and immune system function. MM is incurable and is characterized by frequent early responses to treatment followed by relapse. The American Cancer Society estimates that nearly 11,000 Americans will die of MM in 2007, and the 5-year survival rate for the disease is approximately 33 percent.

Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, GX15-070, is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X is also developing a small molecule that induces apoptosis in p53-defective cancers. Gemin X is privately held and is located in Montreal, Quebec and Malvern, Pennsylvania. For additional information please visit Gemin X at www.geminx.com

Contact

MacDougall Biomedical Communications
Jennifer Greenleaf, 508-647-0209
or
Gemin X Biotechnologies
Sherri Carenzo, 610-640-5735 Ext. 16
scarenzo@geminx.com


'"/>




Page: 1 2

Related medicine technology :

1. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
2. Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:3/4/2015)... March 4, 2015 The March 3, 2015, order from ... must change their products, labels to clarify the drugs, intended ... and stroke is necessary to protect the public from injury ... partner at Simmons Hanly Conroy . The ... that the products – currently taken by millions of U.S. ...
(Date:3/4/2015)... CITY, Kan. , March 4, 2015   ... a pet therapeutics company focused on the licensing, development ... today announced that it will present at the ... 10-12, 2015, at the Loews Miami Beach Hotel in ... Steven St. Peter , M.D., President and Chief ...
(Date:3/4/2015)... N.J. , March 4, 2015  Bayer ... Drug Administration (FDA) has accepted the company,s Biologics ... Factor VIII compound.  Bayer is seeking FDA approval ... for the treatment of hemophilia A in children ... to continually bringing new therapies to hemophilia A ...
Breaking Medicine Technology:Simmons Hanly Conroy, LLC: FDA Orders Label Warnings on Testosterone Drugs Concerning Normal Aging Use and Heart Attack-Stroke Risks 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3
... , May 10 /PRNewswire-Asia/ -- On April ... cases with Beijing Un-Assegai Technical &,Trade Co. Ltd. (hereinafter referred ... China , as claimant and U.S. Abbott,Laboratories (Abbott U.S.; ... by the,China International Economic and Trade Arbitration Commission (CIETAC), which,has ...
... , Fla., May 10 Dr. Richard ... with newly diagnosed type 1 diabetes for Protege Encore, a ... of two Phase III studies testing the safety and efficacy ... as Protege, has completed enrollment of more than 530 subjects ...
Cached Medicine Technology:Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes 2
(Date:3/4/2015)... March 05, 2015 Understanding China’s New ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/UnderstandingChinaMDRegs ... revamped regulations for medical devices in China. , ... devices — research and development, approval, manufacturing, distribution, and ... those currently in development as well as those that ...
(Date:3/4/2015)... NV (PRWEB) March 04, 2015 In the ... the fight that is the main event. For UFC ... that fight will be for the UFC Featherweight Championship. Brazilian ... brash, often out-spoken native of Ireland, Conor “Notorious” McGregor. UFC ... Grand Garden Arena in Las Vegas, NV. , When it ...
(Date:3/4/2015)... 2015 When people talk about venues being ... spread across numerous genres, the Houston Rodeo will ... night during the annual livestock show and rodeo, one popular ... other activities being held at the event. The 2015 show ... that will try and get the festival its largest attendance ...
(Date:3/4/2015)... TROY Healthcare Solutions will be introducing TROY ... level of security for prescriptions, in Houston, Texas on ... Center located at 6633 Travis Street from 7 AM ... TROY Healthcare Solutions will host a continental breakfast. Starting ... presentations each hour to introduce attendees to TROY Secure ...
(Date:3/4/2015)... March 04, 2015 The ability ... in density assessment and help improve breast cancer ... abstracts accepted for presentation at the European Congress ... Ten abstracts - eight posters and 2 session ... automated breast density and quantitative breast imaging software ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 2Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 3Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 3Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 3Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5
... completion may boost patient compliance, outcomes, researchers say , , ... antibiotic called moxifloxacin in combination with other drugs could ... takes to cure patients with drug-treatable tuberculosis, according to ... result in patients failing to complete their drug therapy, ...
... highly recruited adapted sports athletesGOLDEN VALLEY, Minn., April 2 ... Center has had a history of developing talented, nationally ... wheelchair basketball and rugby. On Thursday, April 9, at ... college letters of intent in the Gym at Courage ...
... announced the release of the first long-range plan for ... million Americans each year. , Opportunities and Challenges in ... Digestive Diseases describes the impact of diseases ranging from ... out priorities for research over the next 10 years. ...
... Holdings, Inc. announced today that it has agreed to ... Physicians Investment Network, LLC, which is owned primarily by ... and certain related parties of OC-PIN. The litigation ... May, 2007 against two of its former directors and ...
... Streamline Health Solutions, Inc. (Nasdaq: STRM ) ... year 2008 financial results for the period ended January 31, ... The Company will conduct a conference call and web ... 4:30 p.m. ET.Interested parties can access the call by dialing ...
... 2 In a press conference today, Colgate and,the ... la Salud,Bucal: Un Mundo de Sonrisas Saludables (Oral Health ... ongoing commitment to quality oral care among the,Hispanic community. ... and lack of familiarity accessing oral,healthcare services, among other ...
Cached Medicine News:Health News:New Antibiotic Could Shorten TB Treatment 2Health News:Courage Center Hosts College Scholarship Signing Ceremony Thursday, April 9, 2009 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 3Health News:IHHI Settles Litigation With OC-PIN 2Health News:Streamline Health to Announce Q4 and Fiscal Year 2008 Financial Results on Thursday, April 9, 2009 2Health News:Streamline Health to Announce Q4 and Fiscal Year 2008 Financial Results on Thursday, April 9, 2009 3Health News:Colgate and the Hispanic Dental Association Proclaim April El Mes de la Salud Bucal to Promote Oral Health Fundamentals Among Hispanics 2Health News:Colgate and the Hispanic Dental Association Proclaim April El Mes de la Salud Bucal to Promote Oral Health Fundamentals Among Hispanics 3
... enables highly sensitive time-resolved fluorescence detection ... fluorophores. These compounds are excited with ... fluorescence lifetimes (several hundred microseconds), large ... profiles at 620 nm. Therefore with ...
... most advanced multi-functional microplate detection system, ... performance without compromising flexibility. ,The ... on the Ultra instrument platform. New ... adds to the flexibility of the ...
... OPTIMA is a fully automated microplate ... different measurement principles:, , Fluorescence Polarization ... Fluorescence , High-Performance Luminescence (flash ... ,It is designed for the ...
... FLUOstar is a flexible multifunction plate reader ... one instrument: fluorescence intensity, time-resolved fluorescence, high-perfomance ... be equipped with injectors that deliver reagent ... fast kinetic cell assays can be performed ...
Medicine Products: